Oxfordshire-headquartered medical device manufacturer Owen Mumford has agreed to a sale to embecta Corp — a global leader in diabetes care technology listed on Nasdaq — in a transaction valued at up to £150 million. Mills & Reeve advised the shareholders of Owen Mumford throughout the transaction.
Owen Mumford, founded in 1952, is a privately held innovator and manufacturer of medical devices and drug-delivery technologies, operating as a trusted partner to many of the world's largest pharmaceutical, biotech and healthcare organisations. Its product portfolio spans drug delivery devices, point-of-care testing, self-injection and pelvic health, anchored by its next-generation Aidaptus auto-injector platform.
The transaction will enable Owen Mumford to expand its product portfolio and capitalise on embecta's commercial presence in more than 100 countries. It brings together Owen Mumford's expertise in device design and drug-delivery systems with embecta's large-scale production capabilities to support future product development programmes.
Mills & Reeve's team was led by partner Alex Kenworthy, supported by senior associate Matthew Lilley and Oxford-based associate Owen Henderson. Other advisers on the transaction included Forvis Mazars as financial adviser to Owen Mumford and its shareholders, and J.P. Morgan Securities as financial adviser to embecta.
Gavin Jones, managing director of Owen Mumford, said: “This is a landmark moment for Owen Mumford. For more than 70 years we have been at the forefront of medical device innovation, and joining embecta gives us the global reach and commercial infrastructure to take that legacy to the next level. The combination of our drug-delivery expertise — particularly the Aidaptus platform — with embecta's scale creates a genuinely exciting opportunity to improve outcomes for patients living with chronic conditions around the world.”
Alex Kenworthy, partner at Mills & Reeve, said: “This acquisition is the culmination of many years of hard work and dedication by generations of the Owen and Mumford families, and represents a tremendous opportunity for Owen Mumford to scale up further, combining a world-class drug-delivery platform with embecta's global commercial reach and creating real potential to improve outcomes for patients around the world.”
The transaction is expected to complete later in 2026.
Source: Mills & Reeve · 30 March 2026